Skip to main content

BioRad Completes $200M Exchange Offer for Senior Notes

NEW YORK, June 1 (GenomeWeb News) - Bio-Rad Laboratories has completed an exchange offer that allowed holders of $200 million worth of senior subordinated notes acquired through a private sale last year to obtain amended, publicly registered notes as of yesterday, the company said.

 

According to Ron Hutton, the treasurer of the Hercules, Calif.-based life sciences firm, Bio-Rad offered the note exchange at the beginning of May to investors that had purchased the 6.125-percent notes, due 2014, in December 2004. The amended notes can be publicly traded, as opposed to the old privately issued notes, Hutton said.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.